- Home
- GRI vs SCNI Comparison
GRI vs SCNI Comparison
Compare GRI & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- SCNI
- Stock Information
- Founded
- GRI 2018
- SCNI 2003
- Country
- GRI United States
- SCNI Israel
- Employees
- GRI N/A
- SCNI N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRI Health Care
- SCNI Health Care
- Exchange
- GRI Nasdaq
- SCNI Nasdaq
- Market Cap
- GRI 3.4M
- SCNI 2.3M
- IPO Year
- GRI N/A
- SCNI N/A
- Fundamental
- Price
- GRI $1.85
- SCNI $2.30
- Analyst Decision
- GRI Strong Buy
- SCNI
- Analyst Count
- GRI 2
- SCNI 0
- Target Price
- GRI $22.00
- SCNI N/A
- AVG Volume (30 Days)
- GRI 140.2K
- SCNI 94.8K
- Earning Date
- GRI 08-13-2025
- SCNI 08-14-2025
- Dividend Yield
- GRI N/A
- SCNI N/A
- EPS Growth
- GRI N/A
- SCNI N/A
- EPS
- GRI N/A
- SCNI N/A
- Revenue
- GRI N/A
- SCNI $658,000.00
- Revenue This Year
- GRI N/A
- SCNI N/A
- Revenue Next Year
- GRI N/A
- SCNI N/A
- P/E Ratio
- GRI N/A
- SCNI N/A
- Revenue Growth
- GRI N/A
- SCNI N/A
- 52 Week Low
- GRI $1.10
- SCNI $1.90
- 52 Week High
- GRI $43.69
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- GRI 68.55
- SCNI 47.02
- Support Level
- GRI $1.53
- SCNI $2.06
- Resistance Level
- GRI $1.75
- SCNI $2.50
- Average True Range (ATR)
- GRI 0.13
- SCNI 0.24
- MACD
- GRI 0.06
- SCNI 0.01
- Stochastic Oscillator
- GRI 100.00
- SCNI 30.38
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.